Affinity- and activity-based probes synthesized from structurally diverse hops-derived xanthohumol flavonoids reveal highly varied protein profiling in Escherichia coli†

Lucas C. Webber, a Lindsey N. Anderson, a Ines L. Paraiso, b Thomas O. Metz, b Ryan Bradley, c,d Jan F. Stevens b and Aaron T. Wright a,e,f

Xanthohumol, the principle prenylflavonoid found in hops (Humulus lupulus) and a reported anti-inflammatory agent, has great potential for pharmaceutical interventions related to inflammatory disorders in the gut. A suite of probes was prepared from xanthohumol and its structural isomer isoaxanthohumol to enable profiling of both protein affinity binding and catalytic enzyme reactivity. The regiochemistry of the reactive group on the probes was altered to reveal how probe structure dictates protein labeling, and which probes best emulate the natural flavonoids. Affinity- and activity-based probes were applied to Escherichia coli, and protein labeling was measured by chemoproteomics. Structurally dependent activity-based probe protein labeling demonstrates how subtle alterations in flavonoid structure and probe reactive groups can result in considerably different protein interactions. This work lays the groundwork to expand upon unexplored cellular activities related to xanthohumol interactions, metabolism, and anti-inflammatory mechanisms.

Introduction

Hops (Humulus lupulus) have been an essential ingredient in the beer making process for over a thousand years.1,2 Beer flavor qualities are due to a variety of biologically relevant secondary metabolites present in hops, including alpha- and beta-humulic acids, terpenes, and flavonoids compounds; all of which have been investigated for potential health-promoting activities.3–5 Of the many flavonoids found in hops, xanthohumol (XN) (Fig. 1), a prenylated (3-methylbut-2-en-1-yl) chalcone, is the most abundant, constituting 0.1–1% of the overall dry weight.6 XN has reported anti-obesity,7–9 anti-cancer,10,11 and anti-inflammatory effects.12,13 Once ingested, XN undergoes numerous transformations, producing various prenylflavonoids through chemical or enzymatic processes, resulting in isoaxanthohumol (IXN) (Fig. 1), and side products 8-prenylnaringenin, and dihydroxanthohumol.14

XN has shown promise in mediating the treatment of inflammation, a common characteristic of many chronic gut-related diseases, and a key feature of a group of gastrointestinal diseases falling under the umbrella of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.15 In vitro studies16 suggest XN is able to upregulate several detoxification metabolic proteins to protect against oxidative stress and increased inflammation (e.g. glutathione-S-transferase, heme oxygenase-1, NAD(P)H-quinone oxidoreductase 1), and downregulate pro-inflammatory factors of NF-κB (e.g. inducible nitric oxide synthase, cytokines, cyclooxygenase-2).

![Xanthohumol (1) chalcone and Isoaxanthohumol (2) flavonone](image-url)

Fig. 1 Xanthohumol (XN, 1) is the principle prenylated chalcone found in hops and can undergo intramolecular cyclization in the presence of acid, heat, or enzyme to form the flavonone isoxanthohumol (IXN, 2).
These related findings coupled with the dietary ubiquity of XN, and a recent clinical trial revealing higher doses of XN is safe and well-tolerated in adult humans, suggest that it has significant potential as an oral therapeutic for alleviation of IBD symptoms. Considering its role as a prevalent natural product, as well as interest in potential XN-based therapeutics for treating inflammation in the human gut in relation to inflammation-induced pathologies, it is crucial to further investigate the interactions related to XN and IXN catabolism resulting in gut-permeable metabolites involved in host-gut microbiome resiliency.

Host microbiome gut bacteria are capable of multiple biochemical transformations altering the activity or toxicity of xenobiotics. As a result, the gut microbiome community taxonomy and function may fluctuate heavily under extended xenobiotic exposure. Chemical drug transformations can be altered by the microbiome, and in turn the microbiome can be altered by the drug. Gut microbes such as Eubacterium ramulus and Eubacterium limosum are capable of metabolizing XN into compounds of variable biological activity. Such activity includes decreased biological activity of the reduced chalcone (DXN), increased biological activity of a potent phytoestrogen (8-PN), and unknown biological activity of the demethylated XN (DMX). As such, it is critical to gain a better understanding of the microbial mechanisms of the proteins, pathways, and catalytic enzymes involved in the direct and/or indirect metabolic conversions of XN in the human host gut microbiome prior to engineering pharmaceutical interventions for XN-based therapeutics in diseases such as IBD.

Herein, to determine the scope and range of XN covalent and non-covalent protein interactions, we developed a suite of affinity- and activity-based probes (ABPs) based on the core chemical structures of XN and IXN (Fig. 2). These probes were designed to capture the diverse structural potential of XN conversions, and to improve and expand upon a prior XN-based probe alkylated only on the B ring, which was used only for labeling mammalian proteins through Michael-type addition. This suite of ABPs aims to profile the range of non-covalent and covalent xanthohumol–protein interactions (Scheme 1).

Ultimately, to fully understand the role XN has with the human microbiome in IBD, both covalent and non-covalent protein target specificity must be determined. To reach beyond the protein interactions occurring at the Michael-acceptor of XN, we aimed to develop photoaffinity-enabled ABPs through insertion of the minimalist, UV-activatable diazirine moiety, allowing for labeling of non-covalent protein–substrate interactions. ABPs based on both the XN and IXN chemical scaffolds allowed us to examine the impact of alkylation site and the binding modes of protein recognition for labeling. We expected the protein labeling affinity for each of the ABPs to vary depending on where the core structure is alkylated through the alteration of hydrogen bond interactions within the binding site of a given protein. From our results, we gained insight into which elements are important for substrate recognition through comparisons of probe protein labeling.

**Results and discussion**

**Probe syntheses**

Activity- and affinity-based probes are comprised of three components: (1) a recognition group for targeting specific proteins of interest, (2) a reactive or photoreactive group to covalently label the protein of interest, and (3) a reporter group, which is commonly an alkyne or azide handle enabling bioorthogonal click chemistry for downstream fluorescence and
enrichment applications. XN contains an intrinsic, although selective, mechanism of covalent protein labeling by way of Michael-type addition at the \(\alpha,\beta\)-unsaturated ketone. To develop ABPs that would profile the range of non-covalent protein targets, we appended a diazirine-alkyne linker to XN and IXN. By alkylating the native core of XN and IXN with either an alkyne linker, or a combination diazirine-alkyne linker, we synthesized a suite of eight ABPs with different protein labeling mechanisms (Fig. 2).

We used purified XN (Hopsteiner, Yakima, WA, GAZ:22223928 (https://purl.obolibrary.org/obo/GAZ_22223928)) extracts from spent hops in lieu of total synthesis. Of the three hydroxyls on XN, only the 4 and 4’ are reactive towards alkylation, with little to no substitution observed on the 2’ hydroxyl (Fig. 1). Alkyne linker 3 was readily synthesized in one step from 5-hexynol using a modified Finkelstein reaction. Diazaire-alkyne linker 4 was sourced commercially (Ambeed, Arlington Heights, IL). Using the linkers 3 and 4, XN probes substituted on the 4’-hydroxyl could be synthesized via Williamson ether synthesis to generate ABPs XN-ABP-1 and XN-ABP-2 (Scheme 2). Complete chromatographic separation of the other alkylation products was not possible. Instead, IXN was selectively protected using MOMCl in DMF to afford 8. Subsequent alkylation of the protected IXN using similar Williamson ether synthesis conditions afforded compounds 9 and 10. Treatment of 9 and 10 with HCl in MeOH and water generated ABPs IXN-ABP-3 and IXN-ABP-4, respectively.

**ABP labeling of chalcone isomerase**

To validate ABP labeling of a protein with a known covalent interaction to XN, we labeled the chalcone isomerase N domain-containing protein (U2Q8X2; \(\sim32.5\) kDa, CHI). CHI is a flavonoid-degrading enzyme found in the anaerobic gut bacteria *Eubacterium ramulus* ATCC 29099 (Taxon: 1256908), catalyzing the reversible transformation of a chalcone (i.e. XN) to a flavanone (i.e. IXN).\(^{27}\) As such, both XN and IXN are expected to be recognized as substrates for this enzyme. However, due to the anaerobic nature of *E. ramulus* and the relative low expression in the native microbe, purified chalcone isomerase N domain-containing protein (HMPREF0373 00112 (https://www.uniprot.org/uniprotkb/U2Q8X2)) was cloned into *E. coli* BL21-Al\(^{27}\). ABPs were applied to a bacterial lysate of *E. coli* BL21-AI over-expressing CHI with incubation at 37 °C, UV-irradiation at 365 nm, click chemistry with the fluorescent reporter picolyl rhodamine-azide, and visualization by fluorescence imaging of proteins separated by SDS-PAGE (Fig. 3). Robust and selective labeling of CHI by XN-ABP-1 and IXN-ABP-1 was confirmed at 5 \(\mu\)M. Notably, labeling by XN-ABP-1 and
IXN-ABP-1 is significantly attenuated without UV irradiation, highlighting that covalent labeling of CHI proceeds through the photoactivatable diazirine moiety and confirming the need and applicability of ABPs with a diazirine linker. As expected, minimal labeling is observed with the alkyne-only IXN-ABP-2 via Michael addition.

To further demonstrate strong probe labeling of CHI, overexpressed CHI in *E. coli* BL21-AI was diluted into the same, but uninduced, strain. After labeling each sample with IXN-ABP-1 or IXN-ABP-1, the samples were irradiated, then visualized with picoyl rhodamine azide using click-chemistry. Separation of proteins by SDS-PAGE followed by fluorescence visualization revealed labeled proteins (Fig. 4). Both IXN-ABP-1 and IXN-ABP-1 showed strong labeling (Fig. 4) even as CHI was increasingly diluted into the background lysate of *E. coli*. Decreased fluorescence was observed concomitant with increased enzyme dilution. Indiscriminate labeling is observed in the heat shock (“HS”, Fig. 4) samples, showing probe selectivity is lost when proteins are denatured demonstrating that enzyme function and/or structure is required for selectivity. Considering the promiscuity of typical diazirine probes, and the polyphenolic structure of XN/IXN, these probes demonstrate strong selectivity for chalcone isomerase when labeling at 5 μM.

**Chemoproteomics profiling of XN-protein interactions**

Chemoproteomics was employed to empirically investigate protein labeling by the suite of ABPs. Whole cell lysates from *E. coli* BL21-AI were individually incubated with each of the eight ABPs, irradiated with UV light for the photoaffinity ABPs, clicked using picoyl biotin-azide, and ABP labeled proteins enriched using streptavidin agarose beads, followed by trypsin digest, and analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The total ion abundances of peptide digest, and analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The total ion abundances of peptide sequences and identified proteins associated with each ABP enriched sample were compiled and tabulated to generate a dataset (ESI Tables†) detailing the degree to which each ABP and sample type enriched for a specific identified protein, and sorted by iBAQ (Intensity Based Absolute Quantification) score.

The photoaffinity probes IXN-ABP-1 and IXN-ABP-1 effectively labeled CHI when compared to no probe control samples. Interestingly, none of the other six probes passed statistical filters. Thus, only modification of the A-ring of XN and IXN as ABPs is tolerated by CHI. The probes employing only an alkyne linker (IXN-ABP-2, IXN-ABP-4, IXN-ABP-2, and IXN-ABP-4) do not show any significant enrichment of CHI. This is predictable, as the only conceivable covalent labeling mechanism of the alkyne-only probes would be a through a Michael-type addition by a free nucleophilic residue near the active site of CHI, of which none are known. Further molecular docking analysis supports that XN and IXN will only bind well to CHI if the B-ring phenol is unmodified.27,28

Despite not all probes effectively labeling CHI, we believed it important to still analyze all ABP protein targets. It is not expected that all proteins that interact with xanthohumols bind through the same mechanism and/or configuration. Looking beyond CHI, a wide variety of protein targets were significantly
enriched by the suite of ABPs. Relative quantification of protein targets labeled by the probe suite was calculated by iBAQ using MaxQuant quantification analysis software (v.1.6.17.0). 732 proteins were identified as having a p value of <0.05 with a 1.5 fold-change versus no probe control samples, and having ≥2 replicate observations across all datasets within each ABP group. Notably, only a single protein was identified as labeled by all eight ABPs, NAD(P)H nitroreductase. More proteins were identified among the photoaffinity ABP subset.

Of the proteins identified by the suite of ABPs, there is a broad range of biological and molecular functions targeted. A significant number of proteins with NAD activity and oxidoreductase activity (32 and 23, respectively) were labeled. Considering the well-established antioxidant activity of xanthohumol, it is unsurprising that numerous oxidoreductases were identified. For instance, prenylated phenols can weakly scavenge reactive oxygen species and may also function as antioxidants through anti-oxidative enzymes. Additionally, xanthohumols are known to exhibit a wide range of biological activities, partially due to their relatively small structure, allowing versatility as a potential substrate. Additionally, the Michael acceptor moiety provides an intrinsic protein cross-linking mechanism. As such, chemoproteomics revealed a wide range of targets in E. coli BL21-AI, including at least 39 proteins associated with transport mechanisms, 66 transferases, 44 lyases and ligases, and 11 hydrolases. In addition, some proteins were identified belonging to lipopolysaccharide synthesis, nucleotide sugar metabolism, and N-glycan biosynthesis (Fig. 5).

To further examine how structural diversity of the probe suite, comparisons were made between probe pairs with one variable isolated (i.e. core scaffold, alkylation site, or labeling mechanism). By calculating the differential iBAQ scores for each protein shared between each pair of ABPs, a relative measure of labeling performance could be determined. Across the board, XN-ABP-1 performs the best in terms of number of proteins identified, unique proteins, CHI labeling efficiency, and iBAQ score and peptide sequence coverage above similar probes. Conversely, XN-ABP-3 had the fewest number of proteins identified compared to the full set of photoaffinity probes, as well as the fewest uniquely identified proteins, suggesting that XN-ABP-3 could be conformationally distinct from the other 3 photoaffinity probes with regards to biological activity. Thus, this may lead to greater selectivity in identified proteins, and decreased labeling efficiency. When the same analysis is conducted using the peptide coverages, the results are similar (Fig. 6). Comparing probes with the same A-ring alkylation sites but differing scaffolds (XN-ABP-1 and IXN-
between these probe pairs. In this bacterial model, it's apparent that only a portion of the biological significance might come from the alkene moiety of XN, yet the potential for other biology activities is high and should be investigated further.

Conclusions

In summary, we have developed a structurally diverse suite of XN and IXN based ABPs, through attachment of alkyn e or diazirine alkyn e linkers to the native substrates. By utilizing multiple core scaffolds, alkylation sites, and labeling mechanisms, we were able to examine how each of these variables affects protein binding within a bacterial model. Initial tests with the known flavonoid degrading enzyme CHI showed that the photoaffinity probes are close mimics for the native substrates. ABPP in *E. coli* BL21 identified a wide range of novel protein targets, and by comparing differential iBAQ scores and peptide coverages between specific probe pairs, we determined XN-ABP-1 and IXN-ABP-1 to be the highest performing ABPs. Despite the importance placed on the intrinsic reactivity of XN towards nucleophilic thiols, we observed minimal evidence in support of widespread protein labeling through a Michael-type addition in a bacterial system. Ongoing work in our group includes application of this refined ABP set to human fecal samples for identification of the molecular interactions of XN and its metabolites with the gut microbiome, and to elucidate how specific bacteria could influence the use of XN as an oral therapeutic for IBD.

Data availability

The data described in this study are openly available at MassIVE at [https://doi.org/doi:10.25345/C55295](https://doi.org/doi:10.25345/C55295) (direct access: ftp://massive.ucsd.edu/MSV000088789/).
Author contributions

Conceptualization (LCW, ATW, TOM); data curation (LNA); formal analysis (LCW, LNA, ATW); funding acquisition (TOM, RB, JFS, ATW); investigation (LCW, ILP, LNA, ATW); methodology (LCW, ATW); resources (VLP); supervision (ATW); validation (LCW); visualization (LCW, LNA); writing – draft (LCW, LNA, ATW); writing – editing (LCW, ILP, LNA, TOM, RB, JFS, ATW); data dissemination (LNA).

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This research was supported by the National Center for Complementary and Integrative Health (NCIHH, R01 AT010271). Data acquisition was performed in the Environmental Molecular Sciences Laboratory (EMSL) under the EMSL project award 51663. EMSL is a DOE Office of Science User Facility sponsored by the Biological and Environmental Research program under Contract No. DE-AC05-76RL01830.

References

11. L. Guthrie and L. Kelly, Bringing microbiome-drug interaction research into the clinic, EBioMedicine, 2019, 44, 708–715.
13. K. Klimek, T. Tyskiewicz, M. Miazga-Karska, A. Debczak, E. Roj and G. Ginalska, Bioactive Compounds Obtained from Polish “Marynka” Hop Variety Using Efficient Two-Step Supercritical Fluid Extraction and Comparison of
Their Antibacterial, Cytotoxic, and Anti-Proliferative Activities In Vitro, *Molecules, 2021, 26, 2366.